Anakinra Biosimilar - Research Grade

Human

IL1R1

>1mg/ml

CHO Cells

Anti-Mouse IL-1R (JAMA-147) In Vivo Antibody - Low Endotoxin (ICH1117)

https://www.imgt.org/mAb-DB/

ICH3002

P14778

Blue ice

The ichor.bio Anakinra Biosimilar (Research Grade) is an unconjugated, non-therapeutic research analog of anakinra, supplied for research use only and not for clinical or diagnostic application. Anakinra is a recombinant form of the human interleukin-1 receptor antagonist (IL-1Ra) that acts on the type I interleukin-1 receptor (IL1R1, UniProt P14778). Unlike a monoclonal antibody, the anakinra molecule is a small recombinant protein antagonist; this biosimilar reproduces that binding activity so that investigators can study IL-1 signaling blockade in a controlled, reproducible reagent. As a research-grade material it is produced to low-endotoxin specifications (typically under 1 EU/mg) and is available in bulk milligram-to-gram quantities, making it suitable as an in-vitro reference standard, a positive control, or a benchmarking tool alongside other IL-1 pathway modulators. It is intended for functional and binding characterization work rather than as a substitute for the licensed therapeutic. Because it targets a human receptor, most applications are in-vitro or in human-cell systems; suitability for any in-vivo model should be independently established by the investigator. IL1R1 (interleukin-1 receptor type 1, UniProt P14778) is the principal signaling receptor for the pro-inflammatory cytokines IL-1 alpha and IL-1 beta. Upon ligand binding, IL1R1 recruits the co-receptor IL-1 receptor accessory protein (IL1RAP) to form a signaling complex that activates MyD88, IRAK kinases, and downstream NF-kB and MAPK pathways, driving expression of inflammatory mediators. The naturally occurring interleukin-1 receptor antagonist (IL-1Ra) binds IL1R1 competitively without triggering co-receptor recruitment, thereby blocking IL-1 signaling. Anakinra is a recombinant IL-1Ra that exploits this mechanism. IL1R1-mediated signaling is central to autoinflammatory conditions, rheumatoid arthritis, and innate immune responses, which makes the receptor and its antagonism a widely studied node in inflammation research.

IL-1RT-1, CD121 antigen-like family member A, Interleukin-1 receptor alpha, IL-1R-alpha, Interleukin-1 receptor type I, p80, Interleukin-1 receptor type 1, IL1R, IL1RA

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Anakinra biosimilar suitable for in vivo studies?

A: Yes — it is a low-endotoxin, in vivo-ready recombinant IL-1 receptor antagonist (IL-1Ra) protein intended for preclinical and in vivo research use only (RUO).

Q: Can I order the Anakinra biosimilar in gram quantities?

A: Yes, it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput laboratory work.

Q: What does the Anakinra biosimilar target?

A: It is a non-therapeutic recombinant IL-1 receptor antagonist (IL-1Ra) protein that acts on IL1R1 for research use.